Skip to content
2000
Volume 13, Issue 4
  • ISSN: 1570-1808
  • E-ISSN: 1875-628X

Abstract

Activation of Notch signalling pathway is triggered by binding of NICD to transcription factor CSL and transcriptional co-activator MAML, which involves in various biological functions as well as progression of diseases. Recent prediction shows suppression of cancer causing genes of this pathway through inhibition of NICD-MAML interaction. Through virtual screening against “NCI Diversity 3” of Zinc database, we identified a potential inhibitor “ZINC01690699” (1-N,4-N-bis[3-(1Hbenzimidazol- 2-yl)phenyl]benzene-1,4-dicarboxamide; 1-N,4-dicarboxamide) possessing highest binding affinity to block the two distinct Binding Sites of NICD to inhibit NICD-MAML interaction and also found the most imperative and essential Binding Site (Site I). Inhibition of this interaction caused by binding of ZINC01690699 is validated by protein-protein docking and the prolonged binding as well as stability of NICD-Inhibitor complex is supported by molecular dynamics simulation. The study not only identifies the best inhibitor but also proposes a potential drug for the treatment of cancers.

Loading

Article metrics loading...

/content/journals/lddd/10.2174/1570180812666150819003634
2016-05-01
2025-05-31
Loading full text...

Full text loading...

/content/journals/lddd/10.2174/1570180812666150819003634
Loading

  • Article Type:
    Research Article
Keyword(s): free energy of binding; MAML; NICD; Notch signalling; potential inhibitor; ZINC01690699
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test